

Notes to Editors:

About Sosei

Sosei Co. Ltd., founded in 1990 by Shinichi Tamura, the former CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofile Platform® (DRP®) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West.

Sosei is also developing its own sales and marketing organization in Japan. The company is capitalising on its extensive global network established over the past 10 years in its successful technology transfer business.

In August 2005, Sosei expanded its international presence through the acquisition of the UK-based private biopharmaceutical company Arakis Limited.

For further information about Sosei, please visit www.sosei.com.

About Arakis

Arakis is a UK based biopharmaceutical company that discovers, develops and commercialises innovative medicinal products based on established drugs and drug templates. Its main therapeutic areas are inflammatory disease and pain.

Arakis has four products in clinical development: NVA237 (formerly AD 237) for chronic obstructive pulmonary disease (COPD) and AD 452 for rheumatoid arthritis (RA) which have both completed Phase IIa trials, AD 337 for fibromyalgia syndrome which has just completed Phase I and AD 923 for cancer breakthrough pain (CBP) in Phase I development. In addition, there is a preclinical pipeline of other opportunities, two exploratory developments and a number of research projects.

For further information about Arakis, please visit www.arakis.com